The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss

Expert Opinion on Biological Therapy

Volumn 3, Issue 3, 2003, Pages 509-517

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Aneamia; Blood substitutes; Modified haemoglobin solution; Oxygen carrier; Surgical blood loss; Transfusion

Indexed keywords

HBOC 301; HEMOGLOBIN; OXYGLOBIN; POLYMERIZED HEMOGLOBIN; RAFFINOSE; UNCLASSIFIED DRUG;

ANEMIA; BLEEDING; BLOOD; BLOOD TRANSFUSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ERYTHROCYTE; HUMAN; NEPHROTOXICITY; OXYGEN TRANSPORT; REVIEW;

ACUTE DISEASE; ANEMIA; ANIMALS; ANOXIA; BLOOD LOSS, SURGICAL; BLOOD SUBSTITUTES; HEMOGLOBINS; HUMANS; OXYGEN CONSUMPTION; POSTOPERATIVE COMPLICATIONS;

BOVINAE;

EID: 0037526517     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.3.509     Document Type: Review

References (40)

1. CHAMBERLAND ME: Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products? Clin. Infect. Dis. (2002) 34:797-805. Thorough review of continued potential threats to the safety of blood and plasma products.
2. EARNSHAW PH: Transfusion alternatives in orthopedic surgery. Transfus. Alt. Transfus. Med (1999) 1(2):13-22.
3. HILL SE: Oxygen therapeutics - current concepts. Can. J. Anaesth. (2001) 48(4 Suppl.):S32-S40. Good review of current status of HBOCs, perfluorocarbons and modified haemoglobin solutions.
4. CENTERS FOR DISEASE CONTROL AND PREVENTION: Public health dispatch: investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb. Mortal. Wkly Rep. (2002) 51(43):973-974.
5. SULLIVAN MT, MCCULLOUGH J, SCHREIBER GB, WALLACE EL: Blood collection and transfusion in the United States in 1997. Transfusion (2002) 42:1253-1260.
6. BIERBAUM BE, CALLAGHAN JJ, GALANTE JO, RUBASH HE, TOOMS RE, WELCH RB: An analysis of blood management in patients having a total hip or knee arthroplasty. J. Bone Joint Surg. Am. (1999) 81(1):2-10.
7. STEHLING LC, DOHERTY DC, FAUST RJ et al.: Practice guidelines for blood component therapy. Anesthesiology (1996) 84(3):732-747.
8. REMY B, DEBY-DUPONT G, LAMY M: Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br. Med. Bull. (1999) 55(1):277-298. Excellent comprehensive review of red blood cell substitutes, perfluorocarbons and modified haemoglobin solutions, including descriptions of their general and clinical characteristics.
9. JAHR JS, NESARGI SB, LEWIS K, JOHNSON C: Blood substitutes and oxygen therapeutics: an overview and current status. Am. J. Ther. (2002) 9(5):437-443.
10. MCNEIL JD, SMITH DL, JENKINS DH, YORK GB, JOSEPHS JD: Hypotensive resuscitation using a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) leads to reversal of anaerobic metabolism. J. Trauma (2001) 50(6):1063-1075.
11. STANDL T, HORN P, WILHELM S et al.: Bovine haemoglobin is more potent than autologous red blood cells in restoring muscular tissue oxygenation after profound isovolaemic haemodilution in dogs. Can. J. Anaesth. (1996) 43(7):714-723.
12. STANDL TG, REEKER W, REDMANN G, KOCHS E, WERNER C, SCHULTE AM ESCH J: Haemodynamic changes and skeletal muscle oxygen tension during complete blood exchange with ultrapurified polymerized bovine haemoglobin. Intensive Care Med. (1997) 23(8):865-872.
13. ARNOLDO BD, MINEI JP: Potential of hemoglobin-based oxygen carriers in trauma patients. Curr. Opin. Crit. Care (2001) 7:431-436.
14. WILLIAMS JP, TSEUDA K, VANDERMEERSCH E, BOURKE DL, JAHR JS: Transfusion requirements in phase III study of HBOC-201 (Hemopure®, hemoglobin glutamer-250, bovine) a bovine hemoglobin based blood substitute. Transfusion (2002) 42(Suppl.):14S.
15. HUGHES GS JR, ANTAL EJ, LOCKER PK et al.: Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit. Care Med. (1996) 24(5):756-764.
16. HAYWARD R, LEFER AM: Administration of polymerized bovine hemoglobin improves survival in a rat model of traumatic shock. Methods Find. Exp. Clin. Pharmacol. (1999) 21(6):427-433.
17. MULLON J, GIACOPPE G, CLAGETT C, MCCUNE D, DILLARD T: Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N. Engl. J. Med. (2000) 342:1638-1643.
18. HUGHES GS JR, YANCEY EP, ALBRECHT R et al.: Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin. Pharmacol. Ther. (1995) 58(4):434-443. Complete description of early trial of HBOC-201, its physiological effects and pharmacokinetics.
19. LEVY JH, GOODNOUGH LT, GREILICH PE et al.: Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J. Thorac. Cardiovasc. Surg. (2002) 124(1):35-42. Important Phase II clinical trial of HBOC-201 in cardiac surgical patients.
20. HESS JR, HILL HR, OLIVER CK, LIPPERT LE, GREENWALT TJ: Alkaline CPD and the preservation of RBC 2,3-DPG. Transfusion (2002) 42(6):747-752.
21. D'ALMEIDA MS, JAGGER J, DUGGAN M, WHITE M, ELLIS C, CIN-YEE IH: A comparison of biochemical and functional alterations of rat and human erythrocytes stored in CPDA-1 for 29 days: implications for animal models of transfusion. Transfus. Med. (2000) 10(4):291-303.
22. HUGHES GS JR, FRANCOM SF, ANTAL EJ et al.: Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J. Lab. Clin. Med. (1995) 126(5):444-451.
23. HUGHES GS JR, FRANCOM SF, ANTAL EJ et al.: Effects of a novel hemoglobin-based oxygen carrier on percent oxygen saturation as determined with arterial blood gas analysis and pulse oximetry. Ann. Emerg. Med. (1996) 27(2):164-169. Good description of the haematopoietic effects of HBOC-201 on normal healthy volunteers.
24. KATZ LM, MANNING JE, MCCURDY S et al.: HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury. Resuscitation (2002) 54:77-87.
25. GONZALEZ P, HACKNEY AC, JONES S et al.: A Phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J. Investig. Med. (1997) 45(5):258-264.
26. KASPER S-M, GRUNE F, WALTER M, AMR N, ERASMI H, BUZELLO W: The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth. Analg. (1998) 87:284-291.
27. SPRUNG J, KINDSCHER JD, WAHR JA et al.: The use of bovine hemoglobin glutamer-250 (Hemopure®) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth. Analg. (2002) 94:799-808.
28. LAMURAGLIA GM, O'HARA PJ, BAKER WH et al.: The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J. Vasc. Surg. (2000) 31(2):299-308.
29. JAHR JS, DULCHAVSKY SA, GARINO JP, MACKENZIE C, STEWART LM, TSUEDA K: Hemodynamic effects of hemoglobin glutamer-250 (HEMOPURE®, HBOC-201) compared to red blood cells in pivotal safety and efficacy study in orthopedic surgery patients. Anesth. Analg. (2002) 94:S330.
30. JAHR JS: A novel blood substitute: use of HBOC-201 (Hemopure®) to decrease need for RBC: results of pivotal trial in orthopedic surgery patients. Crit. Care Med. (2002) 29(12 Suppl.):S243.
31. JAHR JS, STEWART LM, MACKENZIE C, BOURKE D, WILLIAMS JP: Pivotal trial phase III study. safety of polymerized bovine hemoglobin (HBOC-201, Hemopure®) as compared to RBC in patients undergoing orthopedic surgery. Anesthesiology (2002) 96:A243.
32. ROHLFS RJ, BRUNER E, CHIU A et al.: Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J. Biol. Chem. (1998) 273(20):12128-12134.
33. ALAYASH AI: Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, of oxidants? Nat. Biotechnol. (1999) 17:545-549.
34. HORN EP, STANDL T, WILHELM S et al.: Bovine hemoglobin increases skeletal muscle oxygenation during 95% artificial arterial stenosis. Surgery (1997) 121(4):411-418.
35. STANDL T, HORN EP, BURMEISTER MA et al.: Bovine hemoglobin restores myocardial tissue tension in dogs with acute critical coronary stenosis and extended hemodilution. Anesthesiology (1999) 90:A697.
36. STANDL T, BURMEISTER MA, HORN EP et al.: Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection. Br. J. Anaesth. (1998) 80:189-194.
37. LEE R, NEYA K, SVIZZERO TA, VLAHAKES GJ: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. (1995) 79(1):236-242.
38. LIPFERT B, STANDL T, DULLMANN J, HELMCHEN U, SCHULTE AM ESCH J, LORKE DE: Histology and ultrastructure of liver and kidney following blood exchange with ultrapurified, polymerised bovine hemoglobin in comparison with hydroxyethyl starch. Lab. Invest. (1999) 79(5):573-582.
39. LIEBERTHAL W, FUHRO R, ANDRY C, VALERI CR: Effects of hemoglobin-based oxygen-carrying solutions in anesthetized rats with acute ischemic renal failure. J. Lab. Clin. Med. (2000) 135(1):73-81.
40. NO AUTHORS LISTED: HEMOPURE® [Hemoglobin glutamer-250 (bovine)]. Product information. Tshepo Pharmaceuticals (Pty) Ltd., Pretoria, Republic of South Africa, April 2001.